Dr.SurgeonPGH said:

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk.

Second this.

BiostatsBrad said:

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

Thank you for spelling out the reasoning rather than just the conclusion.

From the other side of the consultation, briefly.

BiostatsBrad said:

...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

• Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
• Published in NEJM, JAMA, Lancet (not press releases)
• Replicated across multiple independent research groups
• Proven cardiovascular and renal benefits beyond weight loss
• Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

Dr.BariatricHTX said:

BiostatsBrad said: ...cardiovascular risk is just another fad...

Same experience, arrived at from the opposite direction.

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.